EGFR and non-small cell lung carcinoma: Furthermore, a phase 2 study in 80 EGFR T790M-positive NSCLC patients treated for intracranial disease progression reported a manageable safety profile of a 160 mg/day dose with 17% of patients requiring dose adjustment [32].